FTY720 News
Most Popular FTY720 Story
Novartis unveils more positive data for oral MS drug Gilenia
Novartis is touting more positive data for Gilenia (FTY720), the company's late-stage oral multiple sclerosis drug. The data, which were presented at the American Academy of Neurology meeting, Read more...
Latest Headlines
- January 21, 2010
- September 30, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
